What Teitur Trophics does

Teitur Trophics ApS is a privately held, clinical-stage biotechnology company founded in 2020 in Aarhus, Denmark, as a spin-out from Aarhus University. The company develops first-in-class cyclic peptide therapeutics derived from the SorCS receptor family (SorCS1-3) for neurodegenerative diseases and related conditions. Its lead drug candidate, TT-P34, is a subcutaneously administered cyclic peptide that reactivates CREB signaling in neurons, simultaneously restoring mitochondrial and lysosomal function and promoting neurotrophic support, with the goal of halting or slowing disease progression in Parkinson's disease, Huntington's disease, Frontotemporal Dementia, and Dementia with Lewy Bodies. A second candidate, TT-P38, applies the same SorCS2-derived mechanism to sensorineural and age-related hearing loss by boosting BDNF production in the cochlea, and a third program targets Duchenne Muscular Dystrophy.

The company's core innovation is a peptide chemistry platform that addresses two long-standing challenges in CNS drug development: blood-brain barrier penetration and patient-friendly subcutaneous administration. Teitur's approach is differentiated from existing Parkinson's therapies, which primarily address dopaminergic symptoms rather than the underlying cellular pathology. The intellectual property base consists of three generations of patent filings (2016, 2020, 2022) covering SorCS-receptor peptide mimetics and lipidated cyclic variants, and the science is founded on pioneering SorCS receptor biology discoveries from Aarhus University. Teitur completed a EUR 28 million Series A in March 2023, supplemented by Innobooster and Eurostars grants, and has progressed TT-P34 through Phase I clinical trials (completed 2026, 12 early-stage Parkinson's patients dosed at CHDR in Leiden) with Phase II in Parkinson's patients planned for early 2027.

Teitur Trophics is pre-revenue and operates a B2B-focused, science-driven business model. The company engages key opinion leaders in movement disorders and neurology, presents at major international scientific conferences (BIO International, AD/PD, MDS), and pursues pharmaceutical partnerships for eventual out-licensing or co-development. Revenue is not generated from commercial product sales today; future revenue is expected to flow from pharmaceutical product sales following regulatory approval and/or from upfront and milestone payments under licensing agreements. The company employs 1-10 staff and is led by co-founder and CEO Simon Molgaard, with a Scientific Advisory Board of six internationally recognized PD experts.

Name

Teitur Trophics

Legal name

Teitur Trophics ApS

Website

https://teiturtrophics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Teitur Trophics is a clinical-stage Danish biotech developing first-in-class SorCS-derived cyclic peptide therapeutics for neurodegenerative diseases, led by TT-P34 for Parkinson's disease. The company targets disease modification by restoring neuronal mitochondrial and lysosomal function.

Ownership category

akta.pro rank

Product category

Peptide Therapeutics for Neurodegenerative Diseases

NAICS

Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Peptide therapeutics
• Neurodegenerative disease treatment
• Cyclic peptide drug development
• Parkinson's disease therapy
• Hearing loss therapeutics

Headquarters

HQ city

Aarhus

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

1. Drug development and commercialization: Teitur Trophics is a clinical-stage biotech company developing proprietary peptide therapeutics for neurodegenerative diseases. As a pre-revenue company, it has not yet commercialized any products. Revenue will be generated through eventual pharmaceutical product sales following regulatory approval, with potential for out-licensing or co-development agreements with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Teitur Trophics is a clinical-stage biotech developing first-in-class SorCS-derived cyclic peptide therapeutics for neurodegenerative diseases. Its lead candidate TT-P34 is a subcutaneously administered cyclic peptide designed to restore mitochondrial and lysosomal function in neurons by reactivating CREB signaling, with Phase I clinical trials completed for Parkinson's disease. The pipeline also includes TT-P38 (a SorCS2-derived peptide for sensorineural hearing loss) and an early program in Duchenne Muscular Dystrophy.

Product overview

Teitur Trophics is a biotech company developing a pipeline of novel cyclic peptide therapeutics targeting neurodegenerative diseases and hearing loss. The company's core products include TT-P34, a first-in-class subcutaneously administered cyclic peptide for Parkinson's disease and other neurodegenerative disorders, and TT-P38, a SorCS2-derived peptide for hearing loss. The peptides are derived from the SorCS receptor family and work by restoring cellular functions including mitochondrial and lysosomal function to halt disease progression.

Differentiator

Problem solved

Functional benefit

Products and services

• TT-P34 First-in-class subcutaneously administered cyclic peptide drug candidate designed to restore mitochondrial and lysosomal function in neurons by reactivating CREB signaling; in clinical development for Parkinson's disease with potential expansion to Huntington's disease, Frontotemporal Dementia, and Dementia with Lewy Bodies.
• TT-P38

Quantifiable outcome

• Phase I clinical trial completed with 12 early-stage Parkinson's disease patients receiving four weeks of treatment followed by four-week safety follow-up
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• NeuraLightcoreTechnology or Integration · 21 January 2026NeuraLight and Teitur Trophics announced a collaboration to integrate NeuraLight's precision brain function biomarker platform into Teitur's upcoming Phase I clinical trial of TT-P34 for Parkinson's disease. The platform uses eye movement-derived measures to provide quantitative assessment of disease-relevant neural pathway function and supports evaluation of TT-P34's potential as a disease-modifying treatment.
• CILcareminorStrategic or Co-development Partner · 5 February 2025CILcare is a French biotech company collaborating with Teitur on the Eurostars-funded RE-HEAR project for hearing loss. CILcare contributes expertise in hearing loss models and delivery methods for the development of novel peptide-based therapeutics targeting sensorineural hearing loss and age-related hearing loss.
• School of Life Sciences at FHNW (University of Applied Sciences Northwestern Switzerland)minorStrategic or Co-development Partner · 5 February 2025FHNW (Fachhochschule Nordwestschweiz) is collaborating with Teitur on the Eurostars-funded RE-HEAR project to advance novel peptide-based therapeutics targeting hidden hearing loss and age-related hearing loss. FHNW contributes innovative hearing loss models for in vivo and in vitro efficacy evaluations.
• Centre for Human Drug Research (CHDR)coreStrategic or Co-development PartnerCHDR is a leading clinical pharmacology institute in Leiden, the Netherlands, with expertise in early phase drug development and biomarker-driven research. CHDR is conducting Teitur's Phase I clinical trial of TT-P34 in both healthy volunteers and Parkinson's disease patients, incorporating clinical assessments alongside biomarker collection from cerebrospinal fluid.
• Scientific Advisory Board memberscoreStrategic or Co-development PartnerScientific Advisory Board includes six internationally recognized experts in Parkinson's disease and translational medicine: Dr. Andrew Siderowf (UPenn), Dr. Ronald Postuma (McGill), Prof. Charlotte Teunissen (Amsterdam UMC), Prof. Nicola Pavese (Newcastle/Aarhus), Dr. Margherita Fabbri (Toulouse), and Prof. Günter Höglinger (LMU Munich). Board provides guidance on Phase II clinical trial design and biomarker endpoints.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Voyager Therapeutics: US clinical-stage biotech developing gene therapy and RNA-based approaches for CNS disorders including Parkinson's disease. Comparable as a clinical-stage CNS biotech pursuing disease-modifying treatments with novel modalities.
• Sage Therapeutics: US clinical-stage CNS biopharmaceutical company developing novel therapeutics for neurological disorders. Comparable as a clinical-stage neuroscience specialist pursuing differentiated CNS mechanisms.
• Alector: US clinical-stage biotech developing immuno-neurology therapeutics for Alzheimer's, FTD, and Parkinson's disease. Directly comparable to Teitur as a clinical-stage neurodegeneration company pursuing novel mechanisms for disease modification.
• Frequency Therapeutics: US clinical-stage biotech developing regenerative therapeutics for hearing loss. Directly comparable to Teitur's TT-P38 program as a peer pursuing disease-modifying treatments for sensorineural and age-related hearing loss.
• Prothena Corporation: Ireland/US clinical-stage biotech developing protein-misfolding-targeted therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Directly comparable disease-modifying neurodegeneration pipeline.
• Zealand Pharma: Danish clinical-stage biopharmaceutical company specializing in peptide-based therapeutics, including metabolic and rare disease programs. Highly comparable to Teitur due to shared Danish origin, peptide platform focus, and clinical-stage profile.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration including Parkinson's and Alzheimer's, with a focus on novel targeted mechanisms and blood-brain barrier delivery. Comparable to Teitur in disease-modifying CNS strategy and clinical stage.
• BioVie Inc. US clinical-stage biotech focused on neurodegenerative disease therapeutics including Parkinson's and Alzheimer's. Comparable in size, stage, and disease-modifying CNS focus to Teitur.
• Decibel Therapeutics: Clinical-stage biotech developing gene-therapy-based treatments for hearing loss (acquired by Regeneron in 2023). Closely aligned with Teitur's TT-P38 program in therapeutic modality and indication.

Broad incumbents

• H. Lundbeck: Danish-established global pharmaceutical company specializing in neurological and psychiatric disorders. Relevant Danish specialty pharma incumbent and a likely potential acquirer or partner for Teitur's CNS pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/teitur-trophics-aps/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teitur Trophics